Summary of Charles River Laboratories FY Conference Call Company Overview - **Company**: Charles River Laboratories (NYSE: CRL) - **New Leadership**: Birgit Girshick is the incoming CEO, succeeding Jim Foster after over 30 years in the role [4][3] Strategic Initiatives - **Acquisitions**: Two acquisitions were made to enhance supply chain integration and alternative methods for Next-Generation Sequencing [5] - **Divestitures**: Agreements were signed for divesting CDMO and Cell Solutions businesses, as well as some European discovery services [6] - **Digital Transformation**: Over $300 million in cumulative cost reductions achieved, with ongoing efforts to modernize operations [7] Market Trends and Client Insights - **Funding Environment**: Positive trends observed in biotech proposal and bookings since summer, with improved funding conditions for companies with strong programs [9][10] - **Client Confidence**: Clients are optimistic about funding and accelerating drug development, with a net book-to-bill ratio above 1 in Q4 2025 [11][12] Regulatory Environment - **FDA and NIH Impact**: Minimal disruption noted from FDA turnover; NIH funding has stabilized, impacting academic clients but not significantly affecting overall business [13][14] AI in Drug Development - **Client Discussions**: Clients are exploring AI's potential to accelerate drug discovery, with around 150 AI-assisted drug programs currently in the clinic [18][19] - **Long-Term Perspective**: AI is viewed as an evolutionary tool rather than a revolutionary change, with expectations for gradual improvements in efficiency [20][22] Financial Outlook - **Share Repurchase Plans**: Stock repurchases are expected in 2026 due to stock price fluctuations and ongoing capital allocation assessments [28] - **Patent Cliff Navigation**: Pharma companies are prepared for upcoming patent expirations, having already restructured and reprioritized their drug programs [29] Segment Performance - **Manufacturing Segment**: Expected mid-single-digit growth, with strong performance in microbial solutions and biologics testing [46][48] - **CRADL Business**: Demand from early-stage biotech clients remains stable but lacks growth momentum; reliant on increased biotech funding for future growth [39][40] Geographic Expansion - **China Market**: China accounts for 15% of total revenue from research models; potential for expanding DSA services is under evaluation [42][43] Conclusion - **Focus Areas**: The primary focus is on returning to growth, executing modernization strategies, and enhancing shareholder value [50]